FDA Approves Eylea Biosimilars Yesafili and Opuviz in AMD

The FDA approved Yesafili and Opuviz, two interchangeable biosimilars for Eylea, from Biocon Biologics and Samsung Bioepis respectively.

• Eylea is treatment from Regenron
• Active ingredient in all treatments is aflibercept
• Approved indications include wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy
• NOTE: Regeneron Gains as RBC Touts Firm’s Defense Against Biosimilars

To contact the reporter on this story:
Cameron Baker in New York at cbaker225@bloomberg.net

To contact the editor responsible for this story:
Zachary Fleming at zfleming2@bloomberg.net

© 2024 Bloomberg L.P. All rights reserved. Used with permission.